Letermovir is now FDA-approved for CMV prophylaxis in high-risk (D+/R-) kidney transplant recipients, and the data in the primary study that led to this approval (Limaye et al., PMID 37279999) is quite convincing that it works well in that population. Outside of this specific indication we have used...